Impact of test and treat with nirmatrelvir/ritonavir to mitigate the epidemic rebound when Zero-COVID ends in Wallis and Futuna

Antoine Brault (1) , Cécile Tran-Kiem (1, 2) , Clément Couteaux (3) , Valérie Olié (4) , Juliette Paireau (1, 4) , Yazdan Yazdanpanah (5) , Jade Ghosn (5) , Guillaume Martin-Blondel (6) , Paolo Bosetti (1) , Simon Cauchemez (1)

1 Modélisation mathématique des maladies infectieuses - Mathematical modelling of Infectious Diseases
2 Collège Doctoral
3 Agence de Santé des îles Wallis & Futuna
4 Santé publique France - French National Public Health Agency [Saint-Maurice, France]
5 IAME (UMR_S_1137 / U1137) - Infection, Anti-microbiens, Modélisation, Evolution
6 Infinity - Institut Toulousain des Maladies Infectieuses et Inflammatoires

Ending Zero-COVID is challenging, particularly when vaccine coverage is low. Considering Wallis and Futuna, a French Zero-COVID territory affected by reluctance to vaccination, low immunity and high levels of comorbidities, we investigate how targeted use of nirmatrelvir/ritonavir (brand name Paxlovid) can complement vaccination and non-pharmaceutical interventions (NPIs) and mitigate the epidemic rebound expected when Zero-COVID ends.

Domaines: Santé publique et épidémiologie; Modélisation et simulation; Maladies infectieuses

Antoine Brault, Cécile Tran-Kiem, Clément Couteaux, Valérie Olié, Juliette Paireau, et al.. Impact of test and treat with nirmatrelvir/ritonavir to mitigate the epidemic rebound when Zero-COVID ends in Wallis and Futuna. 2022. ⟨hal-03770270v1⟩